



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Van Gelder

Title: Process for Amplifying a Target Polynucleotide Sequence Using a Single Primer-Promoter Complex

Docket No.: LBS-001Con3

Serial No.: 09/713,545

Filed: November 15, 2000

Due Date:

Examiner: Leffers

Group Art Unit: 1636

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information qualifies as prior art or is material as that term is defined in 37 C.F.R. §1.56(b).

() In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application other than a continued application, within three months of the date of entry into the national stage of the above-identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, no fee is required, or before the mailing of a first Office Action after the filing of a request for continued examination under §1.114.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in accordance with §1.97(e) as set forth below; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

(XX) In accordance with §1.97(d), this Information statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Therefore, included are: Certification in Accordance with §1.97(e); and the fee of \$180.00 as set forth in §1.17(p).

(XX) In accordance with §1.97(e), the certification must state either of the following:

() Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

(XX) No item of information in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

(**XX**) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith, except for copies of U.S. patents.

(XX) All listed references are in the English language.

Respectfully submitted,

Barbara J. Luther

Barbara J. Luther
Registration No. 33,954

The Luther Law Firm
12198 E. Columbine Dr.
Scottsdale, AZ 85259
(480) 275-8302



Substitute for Form 1449A/PTO
INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known

Application Number 09/713,545

Filing Date November 15, 2000

First Named Inventor Van Gelder

Group Art Unit 1636

Examiner Name Leffers

Sheet 1 of 4

Attorney Docket No: LBS-001Con3

US PATENT DOCUMENTS

Examiner Initial *	Cite No. *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
--------------------	------------	---------------------	------------------	---	---

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code – Number – Kind Code (if known)				

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AKOWITZ, ALFRED , et al., "A novel cDNA/PCR strategy for efficient cloning of small amounts of undefined RNA", <u>Gene</u> 81, (1989),295-306	
		ALDERSON, RALPH F., et al., "Modulation of neuronal choline acetyltransferase activity by factors derived from cultures of non-neuronal cells from the CNS" <u>Int. J. Devl. Neurosci</u> 7, (1989),309-322	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)
• EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Best Available Copy



Substitute Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 09/713,545

Filing Date November 15, 2000

First Named Inventor Van Gelder

Group Art Unit 1636

Examiner Name Leffers

Sheet 2 of 4

Attorney Docket No: LBS-001Con3

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ASNA, NITZA , et al., "Factor C from rabbit liver", <u>J. Biol. Chem</u> 264, (1989),5245-5252	
		BELYAVSKII, A. J., et al., "Amplification of total cDNA in vitro", <u>Biochemistry</u> 575, (1988),1498-1501	
		BELYAVSKY, A. , et al., "PCR-based cDNA library construction: general cDNA libraries at the level of a few cells", <u>Nucl. Acids Res.</u> 17, (1989),2919-2932	
		BERGER, SHELBY L., et al., "Reverse transcriptase and its associate ribonuclease H: interplay of two enzyme activities controls the yield of single-stranded complementary deoxyribonucleic acid", <u>Biochemistry</u> 22, (1983),2365-2372	

EXAMINER

DATE CONSIDERED




Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/713,545
		Filing Date	November 15, 2000
		First Named Inventor	Van Gelder
		Group Art Unit	1636
		Examiner Name	Leffers
Sheet 3 of 4		Attorney Docket No: LBS-001Con3	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BOUVIER, MICHEL , et al., "Two distinct pathways for cAMP-mediated down-regulation of the beta2-adrenergic receptor", <u>J. Biol. Chem.</u> 264, (1989),16786-16792	
		BROWN, NICHOLAS H., et al., "Functional cDNA libraries from Drosophila embryos", <u>J. Mol. Biol.</u> 203, (1988),425-437	
		BRYSCHE, WOLFGANG , et al., "RNA probes, transcribed from synthesis DNA, for in situ hybridization", <u>Nucl. Acid Res.</u> 16, (1988),2333	
		BUTLER, EUGENE T., et al., "Bacteriophage SP6-specific RNA polymerase", <u>J. Biol. Chem.</u> 257, (1982),5772-5778	

EXAMINER

DATE CONSIDERED



PTO/SB/08A(08-03)
Approved for use through 07/31/2008. OMB 0651-0031
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO
INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known	
Application Number	09/713,545
Filing Date	November 15, 2000
First Named Inventor	Van Gelder
Group Art Unit	1636
Examiner Name	Leffers
Sheet 4 of 4	Attorney Docket No: LBS-001Con3

Filed: _____

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)
• EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Best Available Copy